claudin 18.2 and fgfr2b as novel targets in gastric cancer
Published 1 year ago • 345 plays • Length 2:17Download video MP4
Download video MP3
Similar videos
-
0:51
claudin 18.2 as an emerging target in gastrointestinal cancers
-
1:07
claudin 18.2: a biomarker for gastric cancer
-
0:58
lb1908: a novel car-t cell therapy targeting claudin 18.2 in gi malignancies
-
1:35
assessing the prevalence of cldn18.2 in gastric/gastroesophageal cancers
-
2:08
targeting cldn18.2 with zolbetuximab in gastric and gej cancer
-
6:00
claudin18.2: an emerging biomarker and its significance as a therapeutic target in g/gej cancers
-
0:57
combined inhibition of parp and vegf in gastric cancer
-
1:58
new study links pkcε activation in cancer to aberrant fgfr2 expression
-
2:56
will zolbetuximab impact the treatment landscape for gastric cancer?
-
2:16
safety and efficacy of a cldn18.2-specific car t-cell therapy in gi adenocarcinoma
-
1:52
iilustro: zolbetuximab, mfolfox6, and nivolumab combinations for gastrointestinal cancer
-
1:44
what role will zolbetuximab play in treating gastric cancer?
-
1:55
dr. kornblum on results of precog 0102 in breast cancer
-
1:28
advances in biomarker-directed therapies for gastric cancer
-
0:32
the potential of biosimilars in cancer treatment
-
2:27
triple angiokinase inhibition of vegf, pdgf and fgf receptors in cancer
-
2:01
fgfr mutations
-
1:07
phase ii results for pembrolizumab monotherapy in metastatic tnbc
-
3:03
targeted therapies for gastroesophageal adenocarcinoma